# Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Clinical Effects of AMG 811 in Subjects With Psoriasis

> **NCT01510951** · PHASE1 · COMPLETED · sponsor: **Amgen** · enrollment: 9 (actual)

## Conditions studied

- Psoriasis

## Interventions

- **DRUG:** AMG 811 or Placebo

## Key facts

- **NCT ID:** NCT01510951
- **Lead sponsor:** Amgen
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-08
- **Primary completion:** 2012-10
- **Final completion:** 2012-10
- **Target enrollment:** 9 (ACTUAL)
- **Last updated:** 2013-03-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01510951

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01510951, "Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Clinical Effects of AMG 811 in Subjects With Psoriasis". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT01510951. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*